{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:15:30Z","timestamp":1794028530995,"version":"4.8.0"},"reference-count":66,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,16]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Malignant histiocytic neoplasms (MHNs) are rare tumors derived from the mononuclear phagocyte system (MPS), encompassing histiocytic sarcoma, Langerhans cell sarcoma, interdigitating dendritic cell sarcoma, and other high-grade MPS lineage tumors. Despite advances in understanding histiocytic neoplasms, MHNs remain diagnostically challenging and lack standardized treatment algorithms. Current classification systems differ in lineage framing and fail to address mixed or ambiguous phenotypes, contributing to diagnostic uncertainty and inconsistent care. To address these gaps, the Histiocyte Society convened an international working group of pathologists and oncologists, including World Health Organization and International Consensus Classification contributors, to harmonize nomenclature, define minimum diagnostic criteria, and develop pragmatic treatment recommendations. Using a modified Delphi process and case-based review, the group formulated &amp;gt;40 consensus statements spanning classification, pathology, molecular testing, clinical evaluation, and therapeutic strategies. Key recommendations include the adoption of a unified MHN designation, use of a minimum immunophenotypic panel, integration of broad molecular profiling, and the documentation of previous hematopoietic malignancy. Treatment algorithms emphasize surgical resection for unifocal disease and targeted therapy or immune checkpoint inhibition for multifocal disease when actionable mutations or programmed death ligand 1 expression are present. These consensus recommendations aim to reduce diagnostic ambiguity, standardize reporting, and improve outcomes for both pediatric and adult patients. Future priorities include international registries to refine risk stratification and biomarker-driven trials exploring targeted therapy, immunotherapy, and combination approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033049","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:06:21Z","timestamp":1774980381000},"page":"275-288","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Consensus recommendations for malignant histiocytic neoplasms (histiocytic, Langerhans, and interdigitating dendritic cell sarcomas)"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5177","authenticated-orcid":false,"given":"Gaurav","family":"Goyal","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7446-6274","authenticated-orcid":false,"given":"Oussama","family":"Abla","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5068-6707","authenticated-orcid":false,"given":"John","family":"Chan","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5456-5961","authenticated-orcid":false,"given":"Eli L.","family":"Diamond","sequence":"additional","affiliation":[{"name":"4Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8090-5448","authenticated-orcid":false,"given":"Benjamin","family":"Durham","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics and Pathology and Laboratory Medicine, Rutgers Cancer Institute, New Brunswick, NJ"},{"name":"6Department of Laboratory Medicine, Rutgers Cancer Institute, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6073-4466","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Emile","sequence":"additional","affiliation":[{"name":"7Paris-Saclay University, Versailles SQY University, INSERM, U981, Assistance Publique-H\u00f4pitaux de Paris, Ambroise-Par\u00e9 Hospital, Smart Imaging, Service de Pathologie, Boulogne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3270-411X","authenticated-orcid":false,"given":"Michael","family":"Girschikofsky","sequence":"additional","affiliation":[{"name":"8Internal Medicine I (Hemostasis, Hematology and Stem Cell Transplantation and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6475-8345","authenticated-orcid":false,"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[{"name":"10Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-0301","authenticated-orcid":false,"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"11Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-6263","authenticated-orcid":false,"given":"Kenneth L.","family":"McClain","sequence":"additional","affiliation":[{"name":"12Section of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine and Texas Children\u2019s Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Rech","sequence":"additional","affiliation":[{"name":"13Division of Hematopathology, Mayo Clinic College of Medicine, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3718-6422","authenticated-orcid":false,"given":"Jennifer","family":"Picarsic","sequence":"additional","affiliation":[{"name":"14Pathology Department, University of Pittsburgh School of Medicine, UPMC Children\u2019s Hospital of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7749","key":"2026071611214789700_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"issue":"3","key":"2026071611214789700_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET Study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"issue":"26","key":"2026071611214789700_bib3","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2018-03-839753","article-title":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","volume":"131","author":"Abla","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2026071611214789700_bib4","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2019003507","article-title":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era","volume":"135","author":"Goyal","year":"2020","journal-title":"Blood"},{"issue":"17","key":"2026071611214789700_bib5","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.2021014343","article-title":"International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults","volume":"139","author":"Goyal","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2026071611214789700_bib6","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/bloodadvances.2024015208","article-title":"Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France","volume":"9","author":"Bigenwald","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"2026071611214789700_bib7","doi-asserted-by":"crossref","first-page":"100268","DOI":"10.1016\/j.modpat.2023.100268","article-title":"Malignant histiocytosis comprises a phenotypic spectrum that parallels the lineage differentiation of monocytes, macrophages, dendritic cells, and Langerhans cells","volume":"36","author":"Ravindran","year":"2023","journal-title":"Mod Pathol"},{"issue":"20","key":"2026071611214789700_bib8","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2026071611214789700_bib9","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2026071611214789700_bib10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026071611214789700_bib11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026071611214789700_bib12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3324\/haematol.2019.230375","article-title":"Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2026071611214789700_bib13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ajh.27263","article-title":"Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis","volume":"99","author":"Ruan","year":"2024","journal-title":"Am J Hematol"},{"issue":"14","key":"2026071611214789700_bib14","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1080\/10428194.2025.2561114","article-title":"PD-L1 expression and response to immune checkpoint inhibitor therapy in malignant histiocytic neoplasms","volume":"66","author":"Ravindran","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2026071611214789700_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2017-10-812495","article-title":"Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes","volume":"131","author":"Kommalapati","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026071611214789700_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.clml.2019.03.026","article-title":"Incidence, clinical features, and outcomes of Langerhans cell sarcoma in the United States","volume":"19","author":"Tella","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2026071611214789700_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2350\/09-03-0622-OA.1","article-title":"Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature","volume":"13","author":"Castro","year":"2010","journal-title":"Pediatr Dev Pathol"},{"issue":"2","key":"2026071611214789700_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41379-020-00673-x","article-title":"The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy","volume":"34","author":"Egan","year":"2021","journal-title":"Mod Pathol"},{"issue":"6","key":"2026071611214789700_bib19","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41379-018-0200-x","article-title":"Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma","volume":"32","author":"Shanmugam","year":"2019","journal-title":"Mod Pathol"},{"issue":"9","key":"2026071611214789700_bib25","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/01.pas.0000131541.95394.23","article-title":"Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy","volume":"28","author":"Hornick","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2026071611214789700_bib20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/his.14909","article-title":"PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte-rich tumours","volume":"83","author":"Ungureanu","year":"2023","journal-title":"Histopathology"},{"issue":"16","key":"2026071611214789700_bib28","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ejca.2015.06.109","article-title":"Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas","volume":"51","author":"Gounder","year":"2015","journal-title":"Eur J Cancer"},{"issue":"suppl 1","key":"2026071611214789700_bib52","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1182\/blood-2024-204398","article-title":"Efficacy of targeted agents and immune checkpoint inhibitors in patients with malignant histiocytosis [abstract]","volume":"144","author":"Rodriguez-Rosario","year":"2024","journal-title":"Blood"},{"issue":"23","key":"2026071611214789700_bib54","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.18632\/oncotarget.4378","article-title":"Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1","volume":"6","author":"Gatalica","year":"2015","journal-title":"Oncotarget"},{"issue":"22","key":"2026071611214789700_bib67","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1182\/bloodadvances.2024013545","article-title":"Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms","volume":"8","author":"Ozkaya","year":"2024  26","journal-title":"Blood Adv"},{"issue":"4","key":"2026071611214789700_bib21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood.2024026655","article-title":"Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia","volume":"146","author":"Silbert","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026071611214789700_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12185-008-0059-6","article-title":"Primary histiocytic sarcoma of the spleen associated with hemophagocytosis","volume":"87","author":"Oka","year":"2008","journal-title":"Int J Hematol"},{"issue":"5","key":"2026071611214789700_bib23","first-page":"e1496","article-title":"Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: a case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations","volume":"5","author":"Montalvo","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"1","key":"2026071611214789700_bib24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12887-025-05539-2","article-title":"An 8-year-old girl with secondary histiocytic sarcoma with BRAF(V600) mutation following T-cell acute lymphoblastic leukemia demonstrating stable disease for 3 years on dabrafenib and trametinib - a case report and literature review","volume":"25","author":"Tan","year":"2025","journal-title":"BMC Pediatr"},{"issue":"6","key":"2026071611214789700_bib26","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00428-025-04230-2","article-title":"Langerhans cell sarcoma is a clinically, biologically, and prognostically heterogeneous \"malignant\" histiocytosis: a systematic review of 88 cases from the literature","volume":"487","author":"Dezzani","year":"2025","journal-title":"Virchows Arch"},{"issue":"4","key":"2026071611214789700_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ctrv.2015.02.011","article-title":"Langerhans cell sarcoma: a systematic review","volume":"41","author":"Howard","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"2026071611214789700_bib29","first-page":"66","article-title":"Histiocytic sarcoma of the base of tongue treated with radical radiotherapy: a case report and review of the literature","volume":"21","author":"Iyizoba-Ebozue","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"2026071611214789700_bib30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12185-007-0008-9","article-title":"Histiocytic sarcoma of the spleen: case report of asymptomatic onset of thrombocytopenia and complex imaging features","volume":"87","author":"Kobayashi","year":"2008","journal-title":"Int J Hematol"},{"key":"2026071611214789700_bib31","doi-asserted-by":"crossref","first-page":"bcr2014209014","DOI":"10.1136\/bcr-2014-209014","article-title":"Spontaneous regression of interdigitating dendritic sarcoma in a patient with concurrent small lymphocytic lymphoma","volume":"2015","author":"Khashab","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"2","key":"2026071611214789700_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12185-017-2202-8","article-title":"Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child","volume":"106","author":"Iwabuchi","year":"2017","journal-title":"Int J Hematol"},{"key":"2026071611214789700_bib33","first-page":"728260","article-title":"Successful treatment of multifocal histiocytic sarcoma occurring after renal transplantation with cladribine, high-dose cytarabine, G-CSF, and mitoxantrone (CLAG-M) followed by allogeneic hematopoietic stem cell transplantation","volume":"2015","author":"Tomlin","year":"2015","journal-title":"Case Rep Hematol"},{"issue":"6","key":"2026071611214789700_bib34","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2022.282207","article-title":"Sirolimus as frontline therapy for PTEN-mutated histiocytic sarcoma","volume":"108","author":"Chohan","year":"2023","journal-title":"Haematologica"},{"issue":"10","key":"2026071611214789700_bib35","doi-asserted-by":"crossref","first-page":"e29166","DOI":"10.1002\/pbc.29166","article-title":"Secondary histiocytic sarcoma with BRAF(V600E) mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy","volume":"68","author":"Venkataraman","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"2026071611214789700_bib36","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/ajh.20913","article-title":"Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant","volume":"82","author":"Abidi","year":"2007","journal-title":"Am J Hematol"},{"issue":"10","key":"2026071611214789700_bib37","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/sj.leu.2403075","article-title":"Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL","volume":"17","author":"Dalle","year":"2003","journal-title":"Leukemia"},{"issue":"10","key":"2026071611214789700_bib38","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1200\/JCO.2010.32.6603","article-title":"Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature","volume":"29","author":"Gergis","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026071611214789700_bib39","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/MPH.0b013e3182580d6e","article-title":"Thalidomide therapy for aggressive histiocytic lesions in the pediatric population","volume":"34","author":"Bailey","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026071611214789700_bib40","doi-asserted-by":"crossref","first-page":"755893","DOI":"10.3389\/fonc.2021.755893","article-title":"Case report: long-term response to radiotherapy combined with targeted therapy in histiocytic sarcoma harboring mutations in MAPK and PI3K\/AKT pathways","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"2026071611214789700_bib41","first-page":"97","article-title":"Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient","volume":"4","author":"Ventura Aguiar","year":"2015","journal-title":"J Nephropathol"},{"issue":"15","key":"2026071611214789700_bib42","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1002\/cncr.26712","article-title":"Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab","volume":"118","author":"Shukla","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"2026071611214789700_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/08880018.2020.1811438","article-title":"Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child: is it time to consider new targets?","volume":"38","author":"Valera","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"issue":"20","key":"2026071611214789700_bib44","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMc1511490","article-title":"Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation","volume":"378","author":"Gounder","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2026071611214789700_bib45","doi-asserted-by":"crossref","first-page":"618","DOI":"10.6004\/jnccn.2022.7001","article-title":"Near complete response to trametinib treatment in histiocytic sarcoma harboring a somatic KRAS mutation","volume":"20","author":"Hu","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2026071611214789700_bib46","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12185-018-2553-9","article-title":"A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib","volume":"109","author":"Kumamoto","year":"2019","journal-title":"Int J Hematol"},{"issue":"3","key":"2026071611214789700_bib47","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00277-020-03941-7","article-title":"Trametinib and dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation","volume":"99","author":"Rassidakis","year":"2020","journal-title":"Ann Hematol"},{"issue":"5","key":"2026071611214789700_bib48","doi-asserted-by":"crossref","first-page":"e28200","DOI":"10.1002\/pbc.28200","article-title":"Secondary histiocytic sarcoma with BRAF(V600E) mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib","volume":"67","author":"Venkataraman","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2026071611214789700_bib49","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.3324\/haematol.2017.179150","article-title":"Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma","volume":"103","author":"Voruz","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"2026071611214789700_bib50","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/ejh.13303","article-title":"Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: a case report and review of the literature","volume":"103","author":"Branco","year":"2019","journal-title":"Eur J Haematol"},{"issue":"16","key":"2026071611214789700_bib51","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1212\/WNL.0000000000000880","article-title":"Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib","volume":"83","author":"Idbaih","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"2026071611214789700_bib53","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/bjh.19380","article-title":"Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis","volume":"204","author":"Karri","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"2026071611214789700_bib55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13014-018-1115-x","article-title":"Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1\/PD-L2 expression and literature review","volume":"13","author":"May","year":"2018","journal-title":"Radiat Oncol"},{"issue":"1","key":"2026071611214789700_bib56","doi-asserted-by":"crossref","first-page":"e27491","DOI":"10.1002\/pbc.27491","article-title":"Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma","volume":"66","author":"Bose","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2026071611214789700_bib57","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.mayocp.2022.05.012","article-title":"Malignant histiocytosis with PD-L1 expression-dramatic response to nivolumab","volume":"97","author":"Campedel","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2026071611214789700_bib58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s13691-022-00562-x","article-title":"A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab","volume":"11","author":"Furui","year":"2022","journal-title":"Int Cancer Conf J"},{"key":"2026071611214789700_bib59","doi-asserted-by":"crossref","first-page":"23247096241274561","DOI":"10.1177\/23247096241274561","article-title":"Pembrolizumab combined with GDP regimen inducing sustained remission in histiocytic sarcoma: a case report","volume":"12","author":"Gao","year":"2024","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"4","key":"2026071611214789700_bib60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.36401\/JIPO-23-11","article-title":"Histiocytic sarcoma treated with pembrolizumab: a case report and literature review","volume":"6","author":"Huff","year":"2023","journal-title":"J Immunother Precis Oncol"},{"issue":"3","key":"2026071611214789700_bib61","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3892\/mco.2022.2569","article-title":"Application of PD-L1 blockade in refractory histiocytic sarcoma: a case report","volume":"17","author":"Imataki","year":"2022","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"2026071611214789700_bib62","doi-asserted-by":"crossref","first-page":"e13741","DOI":"10.1111\/crj.13741","article-title":"Primary pulmonary histiocytic sarcoma with high PD-L1 expression benefited from immunotherapy: a case report and bioinformatic analysis","volume":"18","author":"Lin","year":"2024","journal-title":"Clin Respir J"},{"issue":"12","key":"2026071611214789700_bib63","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1097\/MS9.0000000000001446","article-title":"Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report","volume":"85","author":"Nguyen","year":"2023","journal-title":"Ann Med Surg"},{"issue":"9","key":"2026071611214789700_bib64","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.3324\/haematol.2022.280948","article-title":"Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma","volume":"107","author":"Zanwar","year":"2022","journal-title":"Haematologica"},{"issue":"13","key":"2026071611214789700_bib65","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.3390\/ijms25137293","article-title":"Long-term remission with novel combined immune-targeted treatment for histiocytic sarcoma accompanied by follicular lymphoma: case report and literature review","volume":"25","author":"Zhang","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/3\/275\/2533904\/blood_bld-2026-033049-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/3\/275\/2533904\/blood_bld-2026-033049-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:22:01Z","timestamp":1784215321000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/3\/275\/567492\/Consensus-recommendations-for-malignant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033049","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,16]]},"published":{"date-parts":[[2026,7,16]]}}}